A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

To join this study, people generally need to be at least 18 years old. You must have advanced melanoma that has the specific NRAS gene change and has already been treated with certain other therapies, like anti-PD-1 or anti-PD-L1 drugs. Your cancer must have shown signs of getting worse despite these previous treatments.

You would also need to be well enough to take part, meaning you can largely look after yourself and handle daily activities with little help. Doctors will also check that your body and organs, like your blood and kidneys, are working well enough. It's also important that your doctors can get a sample of your tumour for testing.

However, you would not be able to join if you have used certain other melanoma drugs in the past, or if you have specific heart, liver, or autoimmune conditions. If cancer has spread to your brain and is causing problems, or if you had severe side effects from previous immune therapies that made you stop them permanently, you might not be suitable for the study.

Taking part in this study would involve regular visits to the hospital or clinic. You would receive the study medication (belvarafenib, with or without cobimetinib or nivolumab) as prescribed by the study doctors. These visits will include checks on your health, blood tests, and scans to see how your body is reacting to the treatment and whether your cancer is responding. The total duration of your participation could vary, but you would be regularly monitored, and the healthcare team will explain the schedule of visits and assessments. There will also be follow-up appointments after you stop taking the study medication.